BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9513400)

  • 1. [Lewis antigens and CA19-9].
    Naka K; Shimojo N
    Nihon Rinsho; 1998 Jan; 56 Suppl 3():117-20. PubMed ID: 9513400
    [No Abstract]   [Full Text] [Related]  

  • 2. [2-->6 Sialyl Le(a) antigen].
    Miyazaki K; Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():663-8. PubMed ID: 16149606
    [No Abstract]   [Full Text] [Related]  

  • 3. [CA50].
    Kawabe T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():645-6. PubMed ID: 16149601
    [No Abstract]   [Full Text] [Related]  

  • 4. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CA19-9].
    Odagiri E
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():642-4. PubMed ID: 16149600
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of Lewis blood-group phenotype and serum CA-19-9 analysis in the diagnosis of diabetic diseases].
    Shimojo N; Okuda K
    Nihon Rinsho; 1990 Dec; 48 Suppl():359-64. PubMed ID: 2086909
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
    Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
    Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA19-9 determination in the management of pancreatic cancer.
    van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
    Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of latex photometric immunoassay for serum CA19-9].
    Eda S; Miyake K; Horii T; Igari J
    Rinsho Byori; 1995 Mar; 43(3):257-62. PubMed ID: 7745831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 19-9 and Lewis antigens in pancreatic cancer.
    Atkins CD
    J Clin Oncol; 2009 May; 27(15):2572-3; author reply 2573. PubMed ID: 19380435
    [No Abstract]   [Full Text] [Related]  

  • 12. Pancreatic cancer.
    Go VL
    Pancreas; 1994 Nov; 9(6):673. PubMed ID: 7846009
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary.
    Pezzilli R; Casadei R; Calculli L; Santini D; Morselli-Labate AM;
    Dig Liver Dis; 2010 Jan; 42(1):73-4. PubMed ID: 19473891
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-Hodgkin's lymphoma of the pancreas with elevated serum CA 19-9 and SPAN-1].
    Ohta T; Hirai M; Kishida T; Tatsumi N
    Rinsho Ketsueki; 1998 Aug; 39(8):611-3. PubMed ID: 9785981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R; Meyer-Wyss B; Herzog U; Tondelli P
    Schweiz Med Wochenschr; 1999 Jan; 129(3):77-9. PubMed ID: 10065510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.